Wall Street brokerages forecast that Crispr Therapeutics AG (NASDAQ:CRSP) will report $59.43 million in sales for the current fiscal quarter, Zacks Investment Research reports. Four analysts have provided estimates for Crispr Therapeutics’ earnings. The highest sales estimate is $76.70 million and the lowest is $14.30 million. Crispr Therapeutics reported sales of $120,000.00 in the same quarter last year, which would suggest a positive year over year growth rate of 49,425%. The firm is scheduled to issue its next earnings report on Monday, February 24th.

On average, analysts expect that Crispr Therapeutics will report full year sales of $272.00 million for the current fiscal year, with estimates ranging from $226.90 million to $289.27 million. For the next financial year, analysts anticipate that the firm will post sales of $30.04 million, with estimates ranging from $2.03 million to $58.10 million. Zacks Investment Research’s sales calculations are a mean average based on a survey of research firms that that provide coverage for Crispr Therapeutics.

Crispr Therapeutics (NASDAQ:CRSP) last posted its earnings results on Monday, October 28th. The company reported $2.40 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.95) by $3.35. The business had revenue of $211.93 million during the quarter, compared to analysts’ expectations of $6.32 million. Crispr Therapeutics had a negative return on equity of 2.60% and a negative net margin of 5.30%.

Several analysts have recently commented on CRSP shares. TheStreet upgraded Crispr Therapeutics from a “d” rating to a “c” rating in a report on Monday, October 28th. Zacks Investment Research cut shares of Crispr Therapeutics from a “hold” rating to a “sell” rating in a research note on Monday, September 30th. Oppenheimer increased their target price on Crispr Therapeutics from $65.00 to $80.00 and gave the company an “outperform” rating in a report on Monday, November 25th. Chardan Capital reaffirmed a “buy” rating and set a $72.50 target price on shares of Crispr Therapeutics in a research note on Monday, November 18th. Finally, Goldman Sachs Group upped their price target on Crispr Therapeutics from $52.00 to $75.00 and gave the company a “neutral” rating in a research report on Tuesday, November 19th. Two equities research analysts have rated the stock with a sell rating, two have given a hold rating, thirteen have issued a buy rating and one has issued a strong buy rating to the company. The company currently has a consensus rating of “Buy” and a consensus target price of $69.54.

Shares of NASDAQ:CRSP traded up $1.66 on Wednesday, reaching $72.37. The company’s stock had a trading volume of 892,934 shares, compared to its average volume of 703,877. The company has a debt-to-equity ratio of 0.06, a quick ratio of 8.32 and a current ratio of 8.32. Crispr Therapeutics has a 52-week low of $22.22 and a 52-week high of $74.00. The company has a 50-day simple moving average of $54.81 and a 200 day simple moving average of $47.38. The company has a market cap of $4.00 billion, a P/E ratio of -21.04 and a beta of 3.30.

In related news, Director Pablo J. Cagnoni sold 7,500 shares of the stock in a transaction that occurred on Tuesday, November 12th. The shares were sold at an average price of $55.00, for a total transaction of $412,500.00. Following the completion of the sale, the director now owns 7,500 shares of the company’s stock, valued at $412,500. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, President Rodger Novak sold 33,618 shares of the company’s stock in a transaction that occurred on Tuesday, November 19th. The shares were sold at an average price of $70.00, for a total transaction of $2,353,260.00. Following the transaction, the president now owns 33,618 shares in the company, valued at approximately $2,353,260. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 56,118 shares of company stock worth $3,620,760. 21.40% of the stock is owned by insiders.

Several hedge funds and other institutional investors have recently made changes to their positions in the company. Millennium Management LLC purchased a new stake in shares of Crispr Therapeutics in the 3rd quarter valued at about $4,366,000. Orbimed Advisors LLC purchased a new position in shares of Crispr Therapeutics in the 3rd quarter worth about $21,167,000. Granahan Investment Management Inc. MA lifted its stake in shares of Crispr Therapeutics by 8.3% during the third quarter. Granahan Investment Management Inc. MA now owns 34,582 shares of the company’s stock worth $1,418,000 after purchasing an additional 2,655 shares in the last quarter. Barclays PLC lifted its position in shares of Crispr Therapeutics by 42.7% during the third quarter. Barclays PLC now owns 13,877 shares of the company’s stock worth $568,000 after purchasing an additional 4,151 shares in the last quarter. Finally, Stifel Financial Corp increased its stake in shares of Crispr Therapeutics by 18.0% in the third quarter. Stifel Financial Corp now owns 9,795 shares of the company’s stock worth $400,000 after buying an additional 1,491 shares during the last quarter. Institutional investors and hedge funds own 49.81% of the company’s stock.

Crispr Therapeutics Company Profile

CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for the treatment of serious human diseases using its regularly interspaced short palindromic repeats associated protein-9 (CRISPR/Cas9) gene-editing platform in Switzerland. Its lead product candidate is CTX001, an ex vivo CRISPR gene-edited therapy for treating patients suffering from dependent beta thalassemia or severe sickle cell disease in which a patient's hematopoietic stem cells are engineered to produce high levels of fetal hemoglobin in red blood cells.

Further Reading: Sell-Side Analysts

Get a free copy of the Zacks research report on Crispr Therapeutics (CRSP)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Crispr Therapeutics (NASDAQ:CRSP)

Receive News & Ratings for Crispr Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Crispr Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.



Source link